EA201791356A1 - Фосфорамидаты для лечения вируса гепатита в - Google Patents

Фосфорамидаты для лечения вируса гепатита в

Info

Publication number
EA201791356A1
EA201791356A1 EA201791356A EA201791356A EA201791356A1 EA 201791356 A1 EA201791356 A1 EA 201791356A1 EA 201791356 A EA201791356 A EA 201791356A EA 201791356 A EA201791356 A EA 201791356A EA 201791356 A1 EA201791356 A1 EA 201791356A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphoramidates
hepatitis
virus
treatment
compounds
Prior art date
Application number
EA201791356A
Other languages
English (en)
Other versions
EA039123B1 (ru
Inventor
Абел Де Ла Роса
Джордж Пейнтер
Грегори P. Блуемлинг
Original Assignee
Эмори Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмори Юниверсити filed Critical Эмори Юниверсити
Priority claimed from PCT/US2015/064338 external-priority patent/WO2016099982A2/en
Publication of EA201791356A1 publication Critical patent/EA201791356A1/ru
Publication of EA039123B1 publication Critical patent/EA039123B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Раскрыты соединения для лечения инфекционных заболеваний и способы лечения таких заболеваний. Соединения представляют собой производные клевудина.
EA201791356A 2014-12-15 2015-12-07 Фосфорамидаты для лечения вируса гепатита в EA039123B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62/091,686 2014-12-15
US62/094,117 2014-12-19
US201562201974P 2015-08-06 2015-08-06
US62/201,974 2015-08-06
PCT/US2015/064338 WO2016099982A2 (en) 2014-12-15 2015-12-07 Phosphoramidates for the treatment of hepatitis b virus

Publications (2)

Publication Number Publication Date
EA201791356A1 true EA201791356A1 (ru) 2017-12-29
EA039123B1 EA039123B1 (ru) 2021-12-08

Family

ID=80632885

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791356A EA039123B1 (ru) 2014-12-15 2015-12-07 Фосфорамидаты для лечения вируса гепатита в

Country Status (1)

Country Link
EA (1) EA039123B1 (ru)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687931A (en) * 1970-03-19 1972-08-29 Syntex Corp Halogenated purine and pyrimidine nucleosides and process therefor
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases

Also Published As

Publication number Publication date
EA039123B1 (ru) 2021-12-08

Similar Documents

Publication Publication Date Title
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
DK3597646T3 (da) Terapeutiske forbindelser egnede til den profylaktiske eller terapeutiske behandling af en hiv-virusinfektion
EA201890731A1 (ru) Модуляторы корового белка гепатита b
EA201790630A1 (ru) Способы получения рибозидов
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
EA201692473A1 (ru) Способы получения замещенных нуклеотидных аналогов
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201892448A1 (ru) Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
IL279078A (en) Combination therapy for the treatment of hepatitis B viral infection
EA201791356A1 (ru) Фосфорамидаты для лечения вируса гепатита в
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
EA201890818A1 (ru) Режим комбинированной терапии для лечения hcv
EA201992054A1 (ru) Циклические сульфамидные соединения и способы их применения
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в
EA201792083A1 (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний